多发性骨髓瘤后发生的急性淋巴细胞白血病为克隆无关的第二原发恶性肿瘤
多发性骨髓瘤(MM)患者发生髓系肿瘤风险为一般人群的11倍,但急性淋巴细胞白血病(ALL)罕见。报告13例MM治疗后发生的B细胞ALL,MM诊断至ALL发病间隔5.4年(范围3.3-10),ALL诊断时中位年龄60岁(范围43-67)。全外显子组测序配对样本显示两种恶性肿瘤来自不同克隆,ALL为克隆无关的第二原发恶性肿瘤,可能代表治疗相关白血病。
要点
- MM患者发生髓系肿瘤风险为一般人群的11倍,但ALL罕见。
- 13例MM后B细胞ALL中,10例(77%)在ALL诊断前接受过自体造血干细胞移植。
- 配对样本全外显子组测序显示MM与ALL来自不同克隆。
核心结论
- MM后发生的ALL为克隆无关的第二原发恶性肿瘤,可能代表治疗相关白血病。
研究设计与样本
- 报告13例多发性骨髓瘤治疗后发生的B细胞急性淋巴细胞白血病病例。
主要发现
- MM诊断至ALL发病间隔为5.4年(范围3.3-10)。
- ALL诊断时中位年龄为60岁(范围43-67)。
- 全部患者MM治疗均包含免疫调节剂,10例(77%)在ALL诊断前接受过自体造血干细胞移植。
- ALL遗传学显示正常核型5例、TP53突变/缺失3例、单体7或7q缺失2例。
- 配对样本全外显子组测序显示MM与ALL两种恶性肿瘤来自不同克隆。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) patients have an 11-fold increased risk of developing myeloid neoplasms compared to the general population; however, acute lymphoblastic leukemia (ALL) is rarely observed. Given that both MM and the majority of ALL are of B cell origin, this raises the question of whether ALL in patients with MM arises from the same clone. We report 13 cases of B-cell ALL following therapy for MM. The interval from MM diagnosis to ALL onset was 5.4 years (range 3.3-10). The median age at the time of ALL diagnosis was 60 years (range 43-67). MM therapy included immunomodulatory agents in all patients and autologous hematopoietic cell transplantation in 10 (77%) patients preceding ALL diagnosis. ALL genetics showed a normal karyotype, TP53 mutation/deletion, and monosomy 7 or 7q deletion in 5, 3, and 2 cases, respectively. Analysis of paired samples of MM and ALL using whole exome sequencing demonstrated that the malignancies arose from different clones. Thus, ALL as a second primary malignancy following MM is not clonally related but could potentially represent a therapy-related leukemia.
引用
- Aldoss I, Capelletti M, Park J, et al. Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. Leukemia. 2018. PMID: 30026571. doi:10.1038/s41375-018-0213-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。